Publications by authors named "A Cataliotti"
Aims: Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction following myocardial infarction (MI) remains uncertain. This study aimed at understanding the effects of Sac/Val on regional function after MI.
View Article and Find Full Text PDFHeart failure with preserved ejection fraction (HFpEF) is a major clinical problem, with limited treatments. HFpEF is characterized by a distinct, but poorly understood, skeletal muscle pathology, which could offer an alternative therapeutic target. In a rat model, we identified impaired myonuclear accretion as a mechanism for low myofiber growth in HFpEF following resistance exercise.
View Article and Find Full Text PDFBackground: Vibrational spectroscopy can be a valuable tool to monitor the markers of cardiovascular diseases. In the present work, we explored the vibrational spectroscopy characteristics of the cardiac tissue in an experimental model of heart failure with preserved ejection fraction (HFpEF). The goal was to detect early cardiac chemical modifications associated with the development of HFpEF.
View Article and Find Full Text PDFArticle Synopsis
- Guanylyl cyclase-A (GC-A) is an important target for drug development because it helps regulate cardiovascular and renal functions, and current research aims to create small molecular activators instead of relying solely on peptides.
- This study utilized high-throughput screening and in silico design to discover small molecules that enhance the effects of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) on GC-A in various cellular experiments.
- The findings revealed a new allosteric binding site on GC-A that small molecules can target selectively, paving the way for potential new cardiovascular therapies that improve the efficacy of ANP and BNP.